NO2012018I1 - Canakinumab eller direkte ekvivalenter derav - Google Patents

Canakinumab eller direkte ekvivalenter derav

Info

Publication number
NO2012018I1
NO2012018I1 NO2012018C NO2012018C NO2012018I1 NO 2012018 I1 NO2012018 I1 NO 2012018I1 NO 2012018 C NO2012018 C NO 2012018C NO 2012018 C NO2012018 C NO 2012018C NO 2012018 I1 NO2012018 I1 NO 2012018I1
Authority
NO
Norway
Prior art keywords
canakinumab
direct equivalents
equivalents
direct
Prior art date
Application number
NO2012018C
Other languages
English (en)
Other versions
NO2012018I2 (no
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9898090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2012018(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO2012018I2 publication Critical patent/NO2012018I2/no
Publication of NO2012018I1 publication Critical patent/NO2012018I1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
NO2012018C 2000-08-22 2012-11-21 Canakinumab eller direkte ekvivalenter derav NO2012018I1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0020685.4A GB0020685D0 (en) 2000-08-22 2000-08-22 Organic compounds
PCT/EP2001/009588 WO2002016436A2 (en) 2000-08-22 2001-08-20 ANTIBODIES TO HUMAN IL-1$g(b)

Publications (2)

Publication Number Publication Date
NO2012018I2 NO2012018I2 (no) 2012-11-21
NO2012018I1 true NO2012018I1 (no) 2012-12-10

Family

ID=9898090

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20030827A NO332609B1 (no) 2000-08-22 2003-02-21 IL-1<beta>-bindende molekyl og anvendelser derav, ekspresjonsvektor, fremgangsmate for fremstilling samt farmasoytisk preparat
NO2012018C NO2012018I1 (no) 2000-08-22 2012-11-21 Canakinumab eller direkte ekvivalenter derav
NO2017052C NO2017052I2 (no) 2000-08-22 2017-10-11 Canakinumab - forlenget SPC

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20030827A NO332609B1 (no) 2000-08-22 2003-02-21 IL-1<beta>-bindende molekyl og anvendelser derav, ekspresjonsvektor, fremgangsmate for fremstilling samt farmasoytisk preparat

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2017052C NO2017052I2 (no) 2000-08-22 2017-10-11 Canakinumab - forlenget SPC

Country Status (37)

Country Link
US (3) US7446175B2 (no)
EP (1) EP1313769B2 (no)
JP (2) JP4271936B2 (no)
KR (2) KR100910789B1 (no)
CN (1) CN100547003C (no)
AR (1) AR035581A1 (no)
AT (1) ATE396206T1 (no)
AU (2) AU9549001A (no)
BE (1) BE2009C057I2 (no)
BR (1) BR0113420A (no)
CA (1) CA2420231C (no)
CY (2) CY1108779T1 (no)
CZ (1) CZ304470B6 (no)
DE (2) DE122009000078I1 (no)
DK (1) DK1313769T4 (no)
EC (1) ECSP034490A (no)
ES (1) ES2305110T5 (no)
FR (1) FR09C0062I2 (no)
GB (1) GB0020685D0 (no)
HK (1) HK1061403A1 (no)
HU (2) HU228159B1 (no)
IL (2) IL154465A0 (no)
LU (1) LU91624I2 (no)
MX (1) MXPA03001590A (no)
MY (1) MY130248A (no)
NL (1) NL300427I1 (no)
NO (3) NO332609B1 (no)
NZ (2) NZ524199A (no)
PE (1) PE20020319A1 (no)
PL (1) PL212480B1 (no)
PT (1) PT1313769E (no)
RU (1) RU2286351C2 (no)
SI (1) SI1313769T2 (no)
SK (1) SK288089B6 (no)
TW (1) TWI321568B (no)
WO (1) WO2002016436A2 (no)
ZA (1) ZA200301275B (no)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2426710A1 (en) * 2000-11-08 2002-10-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
MXPA05002514A (es) 2002-09-06 2005-05-27 Amgen Inc Anticuerpo monoclonal anti-il-1r1 humano terapeutico.
US7101978B2 (en) * 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
WO2004067568A2 (en) * 2003-01-24 2004-08-12 Applied Molecular Evolution, Inc Human il-1 beta antagonists
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
WO2004100987A2 (en) * 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat neointimal hyperplasia
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
ES2523147T3 (es) * 2004-02-26 2014-11-21 Baylor Research Institute Composiciones y métodos para el tratamiento sistémico de la artritis
AU2012213934B9 (en) * 2005-01-26 2013-07-25 Amgen Fremont Inc. Antibodies against interleukin-1 beta
ES2395953T3 (es) 2005-01-26 2013-02-18 Amgen Fremont Inc. Anticuerpos frente a interleucina-1 beta
GB0509512D0 (en) * 2005-05-10 2005-06-15 Novartis Ag Organic compounds
ES2827247T3 (es) * 2005-06-21 2021-05-20 Xoma Us Llc Anticuerpos y fragmentos de los mismos que se unen a IL-1beta
JP2009511545A (ja) * 2005-10-14 2009-03-19 ノボ・ノルデイスク・エー／エス Ｉｌ−１インヒビターを使用する糖尿病の治療
PL2848258T3 (pl) * 2005-10-26 2018-06-29 Novartis Ag Leczenie rodzinnej gorączki śródziemnomorskiej przeciwciałami przeciwko IL-1beta
WO2007120828A1 (en) * 2006-04-14 2007-10-25 Novartis Ag Use of il-i antibodies for treating ophthalmic disorders
EP3124045A3 (en) 2006-12-20 2017-05-03 Xoma (Us) Llc Treatment of il-1 beta related diseases
CL2008001071A1 (es) * 2007-04-17 2009-05-22 Smithkline Beecham Corp Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
EP1997832A1 (en) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
EP2152308A1 (en) * 2007-05-29 2010-02-17 Novartis Ag New indications for anti- il-i-beta therapy
SI2391650T1 (sl) 2007-12-20 2015-03-31 Xoma (Us) Llc Postopki za zdravljenje protina
KR20110014607A (ko) 2008-04-29 2011-02-11 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
EP2297208A4 (en) 2008-06-03 2012-07-11 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
NZ589434A (en) 2008-06-03 2012-11-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2009149370A1 (en) * 2008-06-06 2009-12-10 Xoma Technology Ltd. Methods for the treatment of rheumatoid arthritis
CA2729949A1 (en) 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
WO2010028273A1 (en) * 2008-09-05 2010-03-11 Xoma Technology Ltd. Methods for improvement of beta cell function
BRPI0919545A2 (pt) * 2008-10-20 2015-12-08 Abbott Lab anticorpos que se ligam a il-18 e métodos de purificar os mesmos
US8298533B2 (en) * 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
US20130122008A1 (en) * 2009-05-06 2013-05-16 Novartis Ag Anti-IL 1- ß Antibody Combination Therapy
US8389474B1 (en) * 2009-07-14 2013-03-05 Alan Anson Wanderer Rationale for IL-1 β targeted therapy to improve harvested organ viability, allograft tolerance, replant success and for conditions characterized by reduced or absent arterial perfusion
BR112012004710A2 (pt) * 2009-09-01 2016-08-16 Abbott Lab imunoglobulinas de domínio variável duplo e uso das mesmas
MX2012004415A (es) * 2009-10-15 2012-05-08 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
DK2493922T3 (en) 2009-10-26 2017-04-24 Hoffmann La Roche Process for preparing a glycosylated immunoglobulin
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
SG185473A1 (en) 2010-05-07 2012-12-28 Xoma Technology Ltd METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
AU2011285852B2 (en) 2010-08-03 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
PE20140229A1 (es) 2010-08-26 2014-03-27 Abbvie Inc Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2697260A1 (en) 2011-04-15 2014-02-19 Merck Patent GmbH Anti- il-1r1 inhibitors for use in cancer
EP2731971A1 (en) 2011-07-12 2014-05-21 Universität Zürich MODULATORS OF THE NLRP3 INFLAMMASOME IL-1ß PATHWAY FOR THE PREVENTION AND TREATMENT OF ACNE
DE102011083595A1 (de) 2011-09-28 2013-03-28 Bayer Pharma AG Inhibition der Wirkung von Interleukin 1 beta zur Behandlung der Endometriose
US9683038B2 (en) 2011-09-30 2017-06-20 Novartis Ag Methods of reducing the risk of experiencing a cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered a qualifying CV event
US20140348848A1 (en) 2011-12-02 2014-11-27 Dhananjay Kaul Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
WO2013090635A2 (en) * 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
EP2791169B1 (en) 2011-12-16 2017-07-19 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
WO2013096516A1 (en) 2011-12-19 2013-06-27 Xoma Technology Ltd. Methods for treating acne
AU2012362326A1 (en) 2011-12-30 2014-07-24 Abbvie Inc. Dual variable domain immunoglobulins against IL-13 and/or IL-17
PT2814843T (pt) * 2012-02-13 2020-06-18 Agency Science Tech & Res Anticorpos monoclonais humanos neutralizantes de il-b
CN103588878A (zh) * 2012-08-15 2014-02-19 江苏泰康生物医药有限公司 一种人源化抗人白细胞介素1 β单克隆抗体及其制备与应用
SG11201503412RA (en) 2012-11-01 2015-05-28 Abbvie Inc Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
WO2014068132A1 (en) * 2012-11-05 2014-05-08 Delenex Therapeutics Ag Binding members to il-1 beta
JP2016502526A (ja) 2012-11-16 2016-01-28 ノバルティス アーゲー 末梢動脈疾患を処置するためのＩＬ−１β結合抗体の使用
EP4001307A1 (en) 2012-12-17 2022-05-25 Cell Medica Inc. Antibodies against il-1 beta
EP2935589A1 (en) 2012-12-18 2015-10-28 Novartis AG Compositions and methods that utilize a peptide tag that binds to hyaluronan
JP2016522793A (ja) 2013-03-15 2016-08-04 アッヴィ・インコーポレイテッド ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質
WO2015083120A1 (en) 2013-12-04 2015-06-11 Novartis Ag USE OF IL-1β BINDING ANTIBODIES
WO2015198243A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
WO2015198240A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
WO2016008851A1 (en) * 2014-07-14 2016-01-21 Boehringer Ingelheim International Gmbh Anti-il-1b antibodies
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP4245376A3 (en) 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
SG11201703428SA (en) 2014-11-10 2017-05-30 Hoffmann La Roche Bispecific antibodies and methods of use in ophthalmology
KR20170082594A (ko) 2014-11-10 2017-07-14 에프. 호프만-라 로슈 아게 항-ang2 항체 및 사용 방법
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
JP2018516931A (ja) 2015-06-04 2018-06-28 ノバルティス アーゲー 末梢動脈疾患を処置するためのｉｌ−１ベータ結合抗体の使用
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
LT3317301T (lt) 2015-07-29 2021-07-26 Novartis Ag Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
MX2018007423A (es) 2015-12-17 2018-11-09 Novartis Ag Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas.
WO2017153936A1 (en) 2016-03-10 2017-09-14 Novartis Ag Chemically modified messenger rna's
US20210292404A1 (en) 2016-07-21 2021-09-23 Novartis Ag Use of il-1beta binding antibody canakinumab for treating or allevating symptoms pulmonary sarcoidosis
EP4252629A3 (en) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
EP3554343A1 (en) 2016-12-14 2019-10-23 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
JP2020524694A (ja) 2017-06-22 2020-08-20 ノバルティス アーゲー がんの処置における使用のためのＩＬ−１β結合性抗体
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
US20200158716A1 (en) * 2017-07-17 2020-05-21 Massachusetts Institute Of Technology Cell atlas of healthy and diseased barrier tissues
EP3710476A1 (en) 2017-08-25 2020-09-23 Novartis AG Use of canakinumab
KR20200052331A (ko) * 2017-09-13 2020-05-14 노파르티스 아게 알코올성 간염의 치료를 위한 il-1b 결합 항체의 용도
MX2020004756A (es) 2017-11-16 2020-08-20 Novartis Ag Terapias de combinacion.
CA3098277A1 (en) 2018-05-09 2019-11-14 Novartis Ag Use of canakinumab
BR112020024351A2 (pt) 2018-06-01 2021-02-23 Novartis Ag moléculas de ligação contra bcma e usos das mesmas
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
GB2575853A (en) * 2018-07-25 2020-01-29 Robert Wotherspoon Hugh IL-1ß binding antibody
CN110818793A (zh) * 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
WO2020039401A1 (en) 2018-08-24 2020-02-27 Novartis Ag Treatment comprising il-1βeta binding antibodies and combinations thereof
EP3878867A4 (en) * 2018-11-07 2022-07-06 Zeda Biopharmaceuticals, Inc. ANTIBODIES THAT BIND TO HUMAN IL-1, METHOD OF PRODUCTION THEREOF AND USE THEREOF
KR20210095165A (ko) 2018-11-19 2021-07-30 프로제너티, 인크. 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스
KR20210106437A (ko) 2018-12-20 2021-08-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
WO2020128613A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1beta binding antibodies
GB201901187D0 (en) 2019-01-29 2019-03-20 Autolus Ltd Treatment of neurotoxicity and/or cytokine release syndrome
US20220144807A1 (en) 2019-02-15 2022-05-12 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP3924055B1 (en) 2019-02-15 2024-04-03 Novartis AG Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2021116789A1 (en) 2019-12-09 2021-06-17 Novartis Ag Anti-interleukin 1 beta antibodies for treatment of sickle cell disease
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置
WO2021123996A1 (en) 2019-12-20 2021-06-24 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
TWI793503B (zh) * 2020-01-20 2023-02-21 美商美國禮來大藥廠 抗IL-1β抗體
WO2021257539A1 (en) * 2020-06-16 2021-12-23 Academia Sinica ANTIBODIES TO INTERLEUKIN-1β AND USES THEREOF
CN115916199A (zh) 2020-06-23 2023-04-04 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
WO2022023907A1 (en) 2020-07-31 2022-02-03 Novartis Ag Methods of selecting and treating patients at elevated risk of major adverse cardiac events
KR20230104651A (ko) 2020-11-06 2023-07-10 노파르티스 아게 Cd19 결합 분자 및 이의 용도
WO2022167916A1 (en) 2021-02-03 2022-08-11 Novartis Ag Use of il-1b binding antibodies for treating neuroinflammatory disorders
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
WO2022249040A1 (en) 2021-05-24 2022-12-01 Novartis Ag Methods for the treatment of osteoarthritis
KR20240023123A (ko) 2021-06-22 2024-02-20 노파르티스 아게 화농성 한선염의 치료에 사용하기 위한 이중특이적 항체

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US534858A (en) * 1895-02-26 Workman s time-recorder
CA1172789A (en) 1980-09-25 1984-08-14 Hideo Kasahara POLYMERIC MATERIAL COMPRISING A POLYAMIDE BONDED TO A COPOLYMER CONTAINING AN IMIDE OF AN .alpha.,.beta. UNSATURATED CARBOXYLIC ACID
US4772685A (en) 1985-10-02 1988-09-20 Merck & Co., Inc. Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
DK590387A (da) * 1986-11-13 1988-05-14 Otsuka Pharma Co Ltd Antistoffer mod interleukin-1
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
DE68925935T2 (de) 1988-10-01 1996-08-14 Otsuka Pharma Co Ltd Antikörper gegen Interleukin-1-beta
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
FR2640146B1 (fr) 1988-12-08 1993-12-24 Commissariat A Energie Atomique Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
CA2018248A1 (en) 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
AU633698B2 (en) 1990-01-12 1993-02-04 Amgen Fremont Inc. Generation of xenogeneic antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP3714683B2 (ja) 1992-07-30 2005-11-09 生化学工業株式会社 抗リウマチ剤
US5429614A (en) 1993-06-30 1995-07-04 Baxter International Inc. Drug delivery system
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
CN1484652A (zh) 2004-03-24
NO2017052I1 (no) 2017-10-11
FR09C0062I2 (fr) 2010-12-31
MY130248A (en) 2007-06-29
NL300427I2 (en) 2010-02-01
US7446175B2 (en) 2008-11-04
NO332609B1 (no) 2012-11-19
BE2009C057I2 (no) 2021-01-28
CY1108779T1 (el) 2012-01-25
MXPA03001590A (es) 2003-06-04
ECSP034490A (es) 2003-03-31
AU9549001A (en) 2002-03-04
NO20030827D0 (no) 2003-02-21
NZ534269A (en) 2006-04-28
HUP0300806A3 (en) 2005-09-28
WO2002016436A3 (en) 2002-06-20
NO20030827L (no) 2003-04-14
US20110256151A1 (en) 2011-10-20
JP2008295456A (ja) 2008-12-11
US8273350B2 (en) 2012-09-25
EP1313769B1 (en) 2008-05-21
KR100910789B1 (ko) 2009-08-04
CN100547003C (zh) 2009-10-07
HK1061403A1 (en) 2004-09-17
BRPI0113420B8 (no) 2021-05-25
LU91624I9 (no) 2018-11-19
TWI321568B (en) 2010-03-11
JP2004506448A (ja) 2004-03-04
US7993878B2 (en) 2011-08-09
HUP0300806A2 (hu) 2003-12-29
US20040063913A1 (en) 2004-04-01
PE20020319A1 (es) 2002-06-11
DK1313769T4 (da) 2011-12-05
CA2420231A1 (en) 2002-02-28
DK1313769T3 (da) 2008-09-15
GB0020685D0 (en) 2000-10-11
SI1313769T1 (sl) 2008-10-31
LU91624I2 (fr) 2010-01-25
ES2305110T5 (es) 2012-03-13
SK288089B6 (sk) 2013-06-03
NO2017052I2 (no) 2018-05-14
CZ304470B6 (cs) 2014-05-21
IL154465A (en) 2010-11-30
PL212480B1 (pl) 2012-10-31
ES2305110T3 (es) 2008-11-01
SK2132003A3 (en) 2003-10-07
KR20080056316A (ko) 2008-06-20
BR0113420A (pt) 2003-07-29
HU228159B1 (en) 2013-01-28
RU2286351C2 (ru) 2006-10-27
PL360358A1 (en) 2004-09-06
ATE396206T1 (de) 2008-06-15
FR09C0062I1 (no) 2010-08-01
AR035581A1 (es) 2004-06-16
SI1313769T2 (sl) 2012-01-31
CZ2003505A3 (cs) 2003-05-14
PT1313769E (pt) 2008-08-26
HUS1300015I1 (hu) 2021-05-28
AU2001295490B2 (en) 2005-06-16
WO2002016436A2 (en) 2002-02-28
CY2009019I1 (el) 2012-01-25
NL300427I1 (en) 2010-02-01
KR20030034140A (ko) 2003-05-01
DE60134148D1 (de) 2008-07-03
IL154465A0 (en) 2003-09-17
JP4271936B2 (ja) 2009-06-03
DE122009000078I1 (de) 2010-03-25
NZ524199A (en) 2004-09-24
BRPI0113420B1 (pt) 2002-02-28
NO2012018I2 (no) 2012-11-21
US20090081732A1 (en) 2009-03-26
EP1313769A2 (en) 2003-05-28
EP1313769B2 (en) 2011-11-09
ZA200301275B (en) 2004-04-02
CA2420231C (en) 2011-04-26
CY2009019I2 (el) 2017-07-12

Similar Documents

Publication Publication Date Title
NO2012018I2 (no) Canakinumab eller direkte ekvivalenter derav
ATE553775T1 (de) Impstoffzusammesetzung
NO20026175L (no) Vaksinesammensetning
IS2932B (is) Fúlvestrant samsetning
NO20004758L (no) Vaksinesammensetning
DK1421841T3 (da) Mejetærsker
IS6915A (is) Lyfjablanda
BR0210619A (pt) composição
DE60125415D1 (de) Formeinsatz
ATA15802000A (de) Pinzette
NO20030917D0 (no) Anvendelse
IS7081A (is) Lyfjablanda
DE50106015D1 (de) Osteosynthesemittel
NO20030239D0 (no) Modifisert virus
AR028336A1 (es) 4-hidroxi-tetrahidropiridonas fenilsubstituidas
DE60116858D1 (de) Zusammensetzung
NO20024322D0 (no) Sekvens
AR028061A1 (es) 2-enamino-cetonitrilos fenil-substituidos
AR027931A1 (es) Antitranspirantes
ITTO20020747A0 (it) Composizione
DE60225412D1 (de) Wanderfeldröhre
ITTO20020745A0 (it) Composizione
AT500246B8 (de) Chokerring
ATA11602000A (de) Sonnenstandsnachführungssystem
ATA12252000A (de) Regensinkkasten